MedTrace Logo

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

NCT07717840 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-07-21

No results posted yet for this study

Summary

This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.

Conditions

  • RSV Respiratory Syncytial Virus

Interventions

BIOLOGICAL

AZD6489

Participants will receive AZD6489 as a single intramuscular injection.

BIOLOGICAL

Licensed RSV vaccine #1

Participants will receive licensed RSV vaccine #1 as a single intramuscular injection.

BIOLOGICAL

Licensed RSV vaccine #2

Participants will receive licensed RSV vaccine #2 as a single intramuscular injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-08
Primary Completion
2026-10-15
Completion
2027-09-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07717840 on ClinicalTrials.gov